Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM17321 in Healthy and Obese Participants
NCT07219589Phase 1Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Mar 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing HM17321 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at Day 113. Started Nov 2025; status: recruiting.
02
Drugs
HM17321
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07219589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219589.